Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US.
Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sarepta Therapeutics (NASDAQ
Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
5 FDA decisions to watch in the third quarter of 2026
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing…
BioMarin Pharmaceutical’s enzyme replacement therapy for a rare genetic disorder called ENPP1 deficiency delivered mixed results…
Sanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the…
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3…
